Nebivolol Puren (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Puren, is a β1‑selective beta blocker presented as an oral dosage form for oral administration. It lowers blood pressure by reducing heart rate and peripheral vascular resistance, and is indicated for the management of hypertension in adult patients.

GNH USA supplies Nebivolol Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a β1‑selective beta‑blocker that acts on the cardiovascular system to control high blood pressure.

Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

Nebivolol may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Dizziness or light‑headedness - Fatigue or tiredness - Nausea - Flushing

Serious or Rare Side Effects: - Severe bradycardia - Symptomatic hypotension - Heart block or atrioventricular conduction disturbances - Bronchospasm in patients with reactive airway disease - Allergic reactions such as rash or angioedema - Hepatic enzyme elevations

When prescribing Nebivolol, clinicians should observe several precautionary measures to ensure patient safety. - Monitor blood pressure: check baseline and periodic readings to assess efficacy. - Assess heart rate: watch for excessive bradycardia, especially in patients with conduction disorders. - Use caution in asthma or COPD: β‑blockade may exacerbate bronchospasm. - Review concomitant beta‑blocker therapy: avoid additive effects that may cause severe bradycardia. - Adjust in hepatic impairment: dose may need modification in patients with liver dysfunction. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined use with other β‑blockers: may cause profound bradycardia or heart block. - Co‑administration with calcium‑channel blockers verapamil or diltiazem: increases risk of AV conduction delay. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): raise nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may diminish antihypertensive effect. - Diuretics: can enhance hypotensive response. - Insulin or oral hypoglycemics: nebivolol may mask hypoglycemia symptoms. - Other antihypertensives (ACE inhibitors, ARBs): additive blood pressure lowering. - SSRIs or other antidepressants: may affect nebivolol metabolism.